Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells

Al-Mahdawi, 2008, The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues, Hum. Mol. Genet., 17, 735, 10.1093/hmg/ddm346 Bedford, 2011, Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets, Nat. Rev. Drug Discov., 10, 29, 10.1038/nrd3321 Bidichandani, 1998, The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure, Am. J. Hum. Genet., 62, 111, 10.1086/301680 Brady, 2000, Fast prediction and visualization of protein binding pockets with PASS, J. Comput. Aided Mol. Des., 14, 383, 10.1023/A:1008124202956 Brownell, 2010, Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ, Mol. Cell, 37, 102, 10.1016/j.molcel.2009.12.024 Bulteau, 2004, Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity, Science (New York, N.Y.), 305, 242, 10.1126/science.1098991 Campuzano, 1996, Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion, Science (New York, N.Y.), 271, 1423, 10.1126/science.271.5254.1423 Capra, 2009, Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure, PLoS Comput. Biol., 5, e1000585, 10.1371/journal.pcbi.1000585 Chen, 2008, Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy, Blood, 111, 4690, 10.1182/blood-2007-09-112904 Cnop, 2013, Diabetes in Friedreich ataxia, J. Neurochem., 126, 94, 10.1111/jnc.12216 Condò, 2006, A pool of extramitochondrial frataxin that promotes cell survival, J. Biol. Chem., 281, 16750, 10.1074/jbc.M511960200 Condò, 2007, In vivo maturation of human frataxin, Hum. Mol. Genet., 16, 1534, 10.1093/hmg/ddm102 Condò, 2010, Molecular control of the cytosolic aconitase/IRP1 switch by extramitochondrial frataxin, Hum. Mol. Genet., 19, 1221, 10.1093/hmg/ddp592 Delatycki, 2009, Evaluating the progression of Friedreich ataxia and its treatment, J. Neurol., 256, 36, 10.1007/s00415-009-1007-y Dhe-Paganon, 2000, Crystal structure of human frataxin, J. Biol. Chem., 275, 30753, 10.1074/jbc.C000407200 Ding, 2006, Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction, J. Med. Chem., 49, 3432, 10.1021/jm051122a Glickman, 2002, The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction, Physiol. Rev., 82, 373, 10.1152/physrev.00027.2001 Greene, 2007, Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia, Nucleic Acids Res., 35, 3383, 10.1093/nar/gkm271 Herman, 2006, Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia, Nat. Chem. Biol., 2, 551, 10.1038/nchembio815 Huang, 2009, MetaPocket: a meta approach to improve protein ligand binding site prediction, OMICS, 13, 325, 10.1089/omi.2009.0045 Huang, 2006, LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation, BMC Struct. Biol., 6, 19, 10.1186/1472-6807-6-19 Issaeva, 2004, Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors, Nat. Med., 10, 1321, 10.1038/nm1146 Kawabata, 2010, Detection of multiscale pockets on protein surfaces using mathematical morphology, Proteins, 78, 1195, 10.1002/prot.22639 Kisselev, 2012, Proteasome inhibitors: an expanding army attacking a unique target, Chem. Biol., 19, 99, 10.1016/j.chembiol.2012.01.003 Koutnikova, 1998, Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase, Hum. Mol. Genet., 7, 1485, 10.1093/hmg/7.9.1485 Kussie, 1996, Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain, Science, 274, 948, 10.1126/science.274.5289.948 Laskowski, 1995, SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions, J. Mol. Graph., 13, 307 Laurie, 2005, Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites, Bioinformatics, 21, 1908, 10.1093/bioinformatics/bti315 Le Guilloux, 2009, Fpocket: an open source platform for ligand pocket detection, BMC Bioinformatics, 10, 168, 10.1186/1471-2105-10-168 Marmolino, 2009, PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy, Cerebellum, 8, 98, 10.1007/s12311-008-0087-z Martelli, 2014, Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation, Front. Pharmacol., 5, 130, 10.3389/fphar.2014.00130 Morris, 2009, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J Comput Chem, 30, 2785, 10.1002/jcc.21256 Musco, 2000, Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin, Structure, 8, 695, 10.1016/S0969-2126(00)00158-1 Oprea, 2000, Property distribution of drug-related chemical databases, J. Comput. Aided Mol. Des., 14, 251, 10.1023/A:1008130001697 Pandolfo, 2009, The pathogenesis of Friedreich ataxia and the structure and function of frataxin, J. Neurol., 256, 9, 10.1007/s00415-009-1003-2 Parkinson, 2013, Clinical features of Friedreich's ataxia: classical and atypical phenotypes, J. Neurochem., 126, 103, 10.1111/jnc.12317 Pastore, 2013, Frataxin: a protein in search for a function, J. Neurochem., 126, 43, 10.1111/jnc.12220 Paupe, 2009, Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia, PLoS One, 4, e4253, 10.1371/journal.pone.0004253 Perdomini, 2014, Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia, Nat. Med., 20, 542, 10.1038/nm.3510 Rentsch, 2013, Synthesis and pharmacology of proteasome inhibitors, Angew. Chem., 52, 5450, 10.1002/anie.201207900 Richardson, 2006, Bortezomib: proteasome inhibition as an effective anticancer therapy, Annu. Rev. Med., 57, 33, 10.1146/annurev.med.57.042905.122625 Rotig, 1997, Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia, Nat. Genet., 17, 215, 10.1038/ng1097-215 Roxburgh, 2012, Small molecules that bind the Mdm2 RING stabilize and activate p53, Carcinogenesis, 33, 791, 10.1093/carcin/bgs092 Rufini, 2011, Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia, Hum. Mol. Genet., 20, 1253, 10.1093/hmg/ddq566 Sakamoto, 2001, Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription, J. Biol. Chem., 276, 27171, 10.1074/jbc.M101879200 Schulz, 2009, Diagnosis and treatment of Friedreich ataxia: a European perspective, Nat. Rev. Neurol., 5, 222, 10.1038/nrneurol.2009.26 Seeliger, 2010, Ligand docking and binding site analysis with PyMOL and Autodock/Vina, J. Comput. Aided Mol. Des., 24, 417, 10.1007/s10822-010-9352-6 Shan, 2013, Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's ataxia YG8R mouse model, Antioxid. Redox Signal., 19, 1481, 10.1089/ars.2012.4537 Shen, 2013, Targeting the ubiquitin-proteasome system for cancer therapy, Expert Opin. Ther. Targets, 17, 1091, 10.1517/14728222.2013.815728 Shindyalov, 1998, Protein structure alignment by incremental combinatorial extension (CE) of the optimal path, Protein Eng., 11, 739, 10.1093/protein/11.9.739 Soucy, 2009, An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer, Nature, 458, 732, 10.1038/nature07884 Tomassini, 2012, Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model, Hum. Mol. Genet., 21, 2855, 10.1093/hmg/dds110 Treier, 1994, Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain, Cell, 78, 787, 10.1016/S0092-8674(94)90502-9 Trott, 2010, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem, 31, 455 Vassilev, 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science (New York, N.Y.), 303, 844, 10.1126/science.1092472 Vaubel, 2013, Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia, Mol. Cell. Neurosci., 55, 50, 10.1016/j.mcn.2012.08.003 Weidemann, 2013, Cardiomyopathy of Friedreich ataxia, J. Neurochem., 126, 88, 10.1111/jnc.12217 Wu, 2012, Specific small molecule inhibitors of Skp2-mediated p27 degradation, Chem. Biol., 19, 1515, 10.1016/j.chembiol.2012.09.015 Yandim, 2013, Gene regulation and epigenetics in Friedreich's ataxia, J. Neurochem., 126, 21, 10.1111/jnc.12254 Yang, 2005, Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells, Cancer Cell, 7, 547, 10.1016/j.ccr.2005.04.029 Yu, 2010, Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere, Bioinformatics, 26, 46, 10.1093/bioinformatics/btp599 Zhang, 2014, Development of inhibitors in the ubiquitination cascade, FEBS Lett., 588, 356, 10.1016/j.febslet.2013.11.003